nesiritide (natrecor) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem repoDB

Active Ingredient History

NOW
  • Now
Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide (BNP), which is normally produced by the ventricular myocardium. Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritid was sold under brand name Natrecor for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

bnp | brain natriuretic peptide | brain natriuretic peptide 32 | brain natriuretic peptide-32 | b-type natriuretic peptide | human brain natriuretic factor-32 | human brain natriuretic peptide-32 | natiuretic peptides | natrecor | natriuretic peptide | natriuretic peptides b | natriuretic peptide type-b | neseritide | nesiritide | nesiritide recombinant | nesritide | recombinant b-type, natriuretic peptide

Organizations (48)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (1)


 

Heart Failure (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Acute Kidney Injury (Phase 3)

Cardiomyopathies (Phase 4)

Cardiopulmonary Bypass (Phase 3)

Cardio-Renal Syndrome (Phase 4)

Cardiovascular Diseases (Phase 4)

Coronary Artery Bypass (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 3)

Death (Phase 3)

Dermatology (Phase 1)

Diabetes Mellitus (Phase 1)

Dyspnea (Phase 4)

Heart Defects, Congenital (Phase 2/Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

Heart Transplantation (Phase 2)

Hyperinsulinism (Early Phase 1)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 4)

Kidney Diseases (Phase 3)

Lung Diseases (Phase 4)

Melanoma (Phase 1)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 4)

Obesity (Phase 1)

Pulmonary Edema (Phase 4)

Renal Insufficiency (Phase 4)

Signs and Symptoms (Phase 1/Phase 2)

Tetralogy of Fallot (Phase 2/Phase 3)

Thoracic Surgery (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 69
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue